AZD1152-HQPA (Barasertib)

Catalog No. A10109

AZD1152-HQPA (Barasertib)是Aurora B的高效抑制剂，Ki值分别为0.36（Aurora B）和1369 nM（Aurora A），与一组其他50种激酶相比具有很高的特异性。

Product Citations

Sakamoto K, .et al. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response, Leukemia, 2018, May 23 PMID: 29795241
Jennifer M. Sahni, .et al. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases, J Biol Chem, 2016, Nov 4; 291(45): 23756-23768 PMID: 27650498

Technical details

Catalog Num	A10109
M. Wt	507.7
Formula	C26H30FN7O3
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	722544-51-6
Synonyms	Barasertib
SMILES	CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCO

Biological Activity

AZD1152-HQPA (Barasertib)是Aurora B的高效抑制剂，Ki值分别为0.36（Aurora B）和1369 nM（Aurora A），与一组其他50种激酶相比具有很高的特异性。

Targets

Aurora B (Cell-free assay)	Aurora A (Cell-free assay)
0.37 nM	1368 nM

Solubility *

In vitro (25°C)	DMSO	93 mg/mL (183.23 mM)
	Water	Insoluble
	Ethanol	3 mg/mL (5.91 mM)
In vivo	2% DMSO+40% PEG 300+2% Tween 80+ddH2O	6 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	19.7 mL	98.48 mL	196.97 mL
0.5 mM	3.94 mL	19.7 mL	39.39 mL
1 mM	1.97 mL	9.85 mL	19.7 mL
5 mM	0.39 mL	1.97 mL	3.94 mL

*The above data is based on the productmolecular weight 507.7 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.